Equities

Ossur hf

Ossur hf

Actions
Health CareMedical Equipment and Services
  • Price (DKK)35.00
  • Today's Change1.55 / 4.63%
  • Shares traded32.27k
  • 1 Year change-11.95%
  • Beta0.6118
Data delayed at least 15 minutes, as of Feb 03 2023 15:59 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Ossur hf is an Iceland-based company that operates within the field of medical equipment and supplies sector. The Company is active in the development and distribution of products in the fields of non-invasive prosthetics, medical braces and supports. The Company is divided into three market segments: Bracing and Supports, which offers products for therapeutic and preventive purposes; Prosthetics, which offers products for amputees, which include sockets, sleeves, prosthetic knees and feet, as well as supporting components, and Compression Therapy, which offers treatment for venous ulcers and edema. The Company's main markets are North America, Europe and Asia. It has subsidiaries in Iceland, the United States, Canada, Mexico, France, the Netherlands, the United Kingdom, Sweden, Norway, Spain, South Africa, China and Australia.

  • Revenue in DKK (TTM)4.95bn
  • Net income in DKK293.11m
  • Incorporated1971
  • Employees3.87k
  • Location
    Ossur hfGrjothals 5REYKJAVIK 110IcelandISL
  • Phone+354 5151300
  • Fax+354 5151366
  • Websitehttps://www.ossur.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
OSSR:CPH since
announced
Transaction
value
RCM Enterprise LLCDeal completed26 Aug 202226 Aug 2022Deal completed21.11%--
Data delayed at least 15 minutes, as of Feb 03 2023 15:59 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
CellaVision AB426.10m82.31m4.01bn234.0048.7310.1237.099.415.275.2727.3025.400.81021.727.643,255,925.0015.6518.7218.5222.7269.2870.7019.3221.741.8514.750.155229.0419.9616.3740.0715.9529.895.92
Synsam AB (publ)3.37bn212.01m4.37bn3.25k20.602.617.031.302.162.1634.3317.020.66592.3414.05--4.20--5.75--76.35--6.31--0.59712.160.621--22.67--126.15------
Xvivo Perfusion AB271.74m12.06m4.91bn118.00408.135.30123.9218.080.62240.622414.0247.940.25361.294.99--1.130.00931.210.0171.5172.394.440.03712.68--0.0070.0060.7322.86126.0424.10----
BICO Group AB1.36bn26.70m5.36bn1.27k200.171.0425.623.930.59230.592332.54114.410.23720.91263.762,342,135.000.4586--0.5044--81.72--1.93--1.55--0.2002--------------
Arjo AB (publ)6.53bn292.49m7.04bn6.69k25.791.517.061.081.641.6436.6427.990.64843.796.14--2.903.444.525.3342.2044.394.475.340.73697.510.45342.6410.025.35-39.7630.52--11.20
Biotage AB997.22m156.39m7.59bn510.0048.667.2534.837.613.613.6123.0424.230.80022.307.023,066,399.0012.5514.8715.3317.8061.2961.3715.6817.181.7511.600.109744.4712.7913.0316.9217.183.334.40
Revenio Group Oyj688.33m160.93m7.98bn191.0049.5912.4341.9911.600.81060.81063.473.230.76787.208.33502,597.8017.8716.3121.1719.9850.9651.8823.2722.281.78--0.205469.8429.0027.4429.6324.259.80-14.40
Ossur hf4.95bn293.11m14.97bn3.87k51.123.3923.453.020.69210.692111.7310.430.55882.366.681,281,617.003.364.814.035.6161.1962.746.017.890.91447.480.43087.19-0.00264.79-33.57-5.916.26--
Elekta AB (publ)9.98bn540.49m18.87bn4.66k36.213.2815.391.892.162.1639.9123.890.59723.402.843,209,640.003.254.845.998.8637.1241.035.448.880.75584.650.384755.055.706.33-7.9755.9812.7119.14
Ambu A/S4.44bn93.00m23.03bn4.41k277.436.1559.985.180.37160.371617.5316.770.68611.926.151,007,938.001.445.081.726.2757.4760.062.097.080.932--0.302227.9410.7413.54-62.35-20.9428.54--
GN Store Nord A/S17.52bn670.00m26.03bn8.17k36.343.3711.811.495.225.22136.8056.290.71873.064.892,423,492.002.959.044.3812.2051.4258.314.1111.120.51925.590.691133.6317.2912.7740.2610.0914.206.15
Getinge AB18.51bn1.63bn41.66bn11.11k27.392.2714.772.259.159.15103.87110.280.58582.715.68--5.213.976.545.1847.4047.998.906.561.5725.030.160539.884.604.69-16.1317.85-7.3423.16
Demant A/S18.66bn2.65bn50.41bn18.13k19.046.42--2.7011.4910.3781.1234.060.73282.055.311,106,131.0010.429.0718.4914.7875.1675.2314.2211.960.587945.490.62120.0023.758.33140.5013.0711.99--
Data as of Feb 03 2023. Currency figures normalised to Ossur hf's reporting currency: Danish Krone DKK

Institutional shareholders

12.96%Per cent of shares held by top holders
HolderShares% Held
SEB Investment Management ABas of 31 Dec 202217.16m4.06%
Invesco Advisers, Inc.as of 31 Dec 20228.26m1.95%
Lannebo Fonder ABas of 30 Jun 20228.09m1.91%
Handelsbanken Fonder ABas of 31 Jan 20235.74m1.36%
ODIN Forvaltning ASas of 31 Dec 20224.98m1.18%
Artisan Partners LPas of 30 Jun 20224.33m1.02%
Royce & Associates LPas of 30 Sep 20222.42m0.57%
Fondita Fund Management Co. Ltd.as of 31 Dec 20221.71m0.40%
Lazard Fr�res Gestion SASas of 30 Jun 20211.13m0.27%
Apo Asset Management GmbHas of 30 Dec 20221.02m0.24%
More ▼
Data from 30 Sep 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.